Conference Call with Ajanta Pharma Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ajanta Pharma announced Q1FY26 results Revenue from operations at Rs 1,303 crore. against Rs 1,145 crore; up 14%. EBITDA at Rs 351 crore. against Rs 330 crore, up 6%; EBITDA at 27%. Profit after tax at Rs 255 crore. against Rs 246 crore; up 4%; PAT at 20%. The mark-to-market forex loss stood at Rs 25 crore. Excluding this impact, EBITDA stood at Rs 376 crore, reflecting a 14% growth, with an EBITDA margin of 29%. PAT grew by 12%, with a PAT margin of 21%. Cashflow from operations (CFO) was Rs 282 crore, EBITDA to CFO conversion of 80%. Free cashflow (FCF) was Rs 209 crore, FCF to PAT conversion of 82%. ROCE stood at a healthy level of 33% and RONW at 26%. Result PDF